Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cardinal Health, Inc. (CAH)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
53.10+0.83 (+1.59%)
At close: 04:00PM EDT
53.10 0.00 (0.00%)
After hours: 04:30PM EDT
Advertisement
Sign in to post a message.
  • R
    Rule the Market
  • J
    Joseph
    Test
  • H
    Henry W
    anyone following on this? looked like a safe entry point for the value divi,
  • W
    Winorlose
    This is what happens when you buy the peak!
  • Y
    Yahoo Finance Insights
    Cardinal Health is down 9.04% to 55.02
  • R
    Raymond
    Embarrassing
  • W
    Wisdom of Crowds
    $CAH and $CVS will be huge winners.....profitable, low valuations, inflation hedges, aging populations, government spending in health care, Covid/vaccination tail winds. Good luck longs....
    Bullish
  • D
    Dave
    From CFRA
    -- In August, we lifted our view on shares of CAH to
    Buy from Hold as we think CAH is attractive at
    current valuations. We see CAH set for better
    growth in its core business in FY 22 and in the
    long-run we think it will likely benefit from
    steadily growing product volumes as baby
    boomers drive higher health care utilization. We
    view the divestiture of the Cordis business,
    CAH’s global manufacturer of cardiology devices
    for $1B as positive. The transaction is slated to
    close in H1 FY 22. Since its 2015 acquisition,
    Cordis was a significant drag for the Medical
    segment, in our view, due to operational
    problems, inventory write-downs, and mounting
    litigation costs.
    ---Consolidation of health insurers, providers, and
    pharmacy benefit managers has been an
    ongoing trend since 2018. This trend could
    pressure CAH's operating margins, in our view,
    as larger customers are able to negotiate lower
    distribution fees.
    --- Our price target is $56, 8.9x our FY 23 EPS
    estimate, lower than CAH’s historical forward P/
    E average of 120x. Risks include a longer-thananticipated rebound in elective procedures due
    to new rising Covid-19 infections, severe
    generic price deflation and contract renewals on
    less favorable terms
  • B
    Bobby
    At this price it's almost a 4% dividend,.great entry price!
  • D
    Dana Point
    4% dividend, listed as undervalued, in the growing health care market, and it is still at a 52 week low. Don't understand.
  • R
    Robert
    DUBLIN, Ohio, Aug. 11, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that it has extended its agreements with CVS Health to distribute pharmaceuticals to retail pharmacies and distribution centers through June 30, 2027.
    Bullish
  • S
    Scott
    I'm considering initiating a position in CAH sometime over the next couple days, assuming it stays in the lower $50 range. If I buy, this will go in the more conservative portion of my IRA portfolio with plans to hold long term, reinvesting dividends along the way. Opinions, positive and negative, appreciated. Thank you!
  • A
    Anonymous
    One of the absolute worst healthcare stocks over the past 12 months. CAH has never recovered from last years $20 price drop.
  • I
    Info
    3.5% dividend, 30% payout ratio, forward PE of 9. Seems like an obvious buy, like CNC was on their ER.

    Opinions?
  • R
    Roger
    Just a big surprise to see the low point of the week be after such a great Earnings report. There must have been something in there that I didn't see that is a big negative. CVS is also down today, but not on the same scale as CAH.
  • C
    C
    From today’s WaPo: ‘Just six companies distributed 75 percent of the pills during this period: McKesson Corp., Walgreens, Cardinal Health, AmerisourceBergen, CVS and Walmart, according to an analysis of the database by The Washington Post. Three companies manufactured 88 percent of the opioids: SpecGx, a subsidiary of Mallinckrodt; Actavis Pharma; and Par Pharmaceutical, a subsidiary of Endo Pharmaceuticals.
    Purdue Pharma, which the plaintiffs allege sparked the epidemic in the 1990s with its introduction of OxyContin, its version of oxycodone, was ranked fourth among manufacturers with about 3 percent of the market.
    The volume of the pills handled by the companies skyrocketed as the epidemic surged, increasing about 51 percent from 8.4 billion in 2006 to 12.6 billion in 2012. By contrast, doses of morphine, a well-known treatment for severe pain, averaged slightly more than 500 million a year during the period.’
    Bearish
Advertisement
Advertisement